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Background: Aberrant crypt foci (ACF) are considered the first identifiable preneoplastic lesion in colorectal
cancer (CRC), and have been proposed as a potential biomarker for CRC risk. Global DNA hypomethylation is an
early event in colorectal carcinogenesis, and long interspersed nuclear element-1 (LINE-1) methylation status is a
well-known surrogate marker for genome-wide DNA methylation levels. Despite the gradual increase in DNA
hypomethylation in the adenoma–carcinoma sequence, LINE-1 methylation in ACF has never been studied.
Moreover, recent studies have reported a field defect for LINE-1 hypomethylation, suggesting that LINE-1 methylation
status in normal mucosa could be used to stratify CRC risk and tailor preventive strategies. Thus, we assessed LINE-1
status by pyrosequencing in rectal ACF and paired normal colorectal mucosa from individuals with sporadic colon
cancer (CC) (n = 35) or adenoma (n = 42), and from healthy controls (n = 70).
Findings: Compared with normal mucosa, LINE-1 in ACF were hypermethylated across all groups (P < 0.0001).
Furthermore, LINE-1 methylation status in normal colorectal mucosa was independent of the presence of adenoma or
CC (P = 0.1072), and did not differ depending on the distance to the adenoma or CC. Interestingly, when we
compared the LINE-1 methylation status in normal mucosa from different segments of the colorectum, we found
higher hypomethylation in the rectum compared with the descending colon (P < 0.0001).
Conclusions: Overall, our results suggest that global hypomethylation is not present in rectal ACF and argues
against the existence of LINE-1 methylation field defect in sporadic colon cancer.
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Background
Aberrant crypt foci (ACF) are considered the first identifi-
able preneoplastic lesion in CRC [1]. ACF show features
that support their potential role as premalignant lesions,
such as dysplasia, monoclonality, and mutations, which
are present in adenomas and carcinomas but not in nor-
mal colon mucosa [2,3]. High-magnification chromoscopic
colonoscopy can detect ACF in vivo [4], and several stu-
dies using chromoendoscopy have shown a higher rate of* Correspondence: mpellise@clinic.ub.es; fprunes@clinic.ub.es
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article, unless otherwise stated.ACF occurrence in patients with CRC and adenomas
compared with healthy individuals [4]. Accordingly, ACF
(especially those located in the rectum) have been pro-
posed as a potential biomarker for CRC risk [5]. Histologi-
cally, ACF can be classified as hyperplastic or dysplastic
[6]. Data from single-center studies have suggested that
dysplastic ACF may correlate with CRC risk, as there is an
increased frequency of dysplastic ACF in individuals with
a normal colon, patients with adenoma, and patients with
CRC [1]. However, other studies have shown conflicting
findings regarding the clinical value of dysplastic ACF
[7-9], and thus, the role of ACF in colorectal carcino-
genesis is still under debate. Although rectal ACF havetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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viduals at high risk for CRC because of their specific his-
tological and molecular features, this is still an area of
uncertainty [10].
Methylation of cytosine residues at CpG dinucleotides
is a major epigenetic modification strongly associated
with transcriptional silencing. Long interspersed element-1
(LINE-1) elements are a type of genomic repetitive ele-
ments that in their full-length form encode the retro-
transposon machinery [11]. LINE-1 methylation status is
a well-known surrogate marker for genome-wide DNA
methylation level. In normal cells, LINE-1 is heavily meth-
ylated [12], whereas cancer cells show LINE-1 hypome-
thylation, leading to chromosomal instability [13]. This
phenomenon occurs early in the colorectal carcinogenesis
[14,15]. However, despite the gradual increase of hypo-
methylation in the adenoma–carcinoma sequence [16],
LINE-1 methylation in ACF has never been studied.
Moreover, recent studies have reported a field defect
in LINE-1 hypomethylation [14,17,18], suggesting that
LINE-1 methylation status in normal mucosa could be
used to stratify CRC risk and tailor preventive strategies.
The aims of this study were to analyze the levels of
LINE-1 methylation in rectal ACF compared with paired
normal colorectal mucosa, and to investigate the putativeFigure 1 Study design. Flow chart summarizing the study design. Long in
DNA extracted from aberrant crypt foci (ACF) and normal colorectal mucos
normal colonoscopy, patients with adenomas, and patients with colon canfield defect of LINE-1 hypomethylation by analyzing the
normal mucosa of patients from three different CRC risk
groups. The analysis was confined to rectal ACF because
of their previously reported higher frequency compared
with other colonic segments, in addition to their useful-




A random selection of patients referred to our hospital for
a diagnostic colonoscopy between 2008 and 2010 was pro-
spectively included in this study. Colonoscopy was per-
formed with high-definition endoscopes (H180; Olympus,
Tokio, Japan). Based on the colonoscopy findings, indi-
viduals were classified into healthy control (n = 70), aden-
oma (n = 42), and colon cancer (CC) (n = 35) groups. The
distal rectum (10 cm) was explored with narrow band im-
aging and then with high-resolution chromoendoscopy
using methylene blue 0.5%. For each individual, biopsy
samples of normal descending colon and rectal mucosa
(with a minimum distance of 10 cm away from any
lesion), and up to three ACF in the rectum were used for
molecular analyses (Figure 1). Patients with rectal cancer
were excluded from the analysis in order to ensure thatterspersed element-1 (LINE-1) methylation analysis was performed in
a samples from three colon cancer risk groups (individuals with a
cer).
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tal neoplasia in all patients. Two different endoscopists
registered the number and features of ACF, and two ex-
pert pathologists characterized all biopsies.
The project was granted approval from institutional
review board of the Hospital Clinic of Barcelona, and
written informed consent was obtained from all
participants.DNA extraction
ACF and normal mucosa biopsies were preserved at −80°C
optimal cutting compound (OCT) and phosphate-buffered
saline (PBS), respectively. DNA was extracted using an All
Prep DNA/RNA Mini Kit (catalog number 80204; Qiagen,
Hilden, Germany) following the manufacturer’s recom-
mendations. DNA and RNA were quantified using a
NanoDrop Spectrophotometer ND-1000 (Thermo Fisher
Scientific).Bisulfite pyrosequencing and LINE-1 methylation analysis
Bisulfite treatment was performed using the EpiTect
Bisulfite kit (catalog number 59104; Qiagen) following
manufacturer’s instructions. Methylation analysis of LINE-
1 promoter was investigated using pyrosequencing-based
methylation analysis [15]. PCR was carried out in a 25 μl
PCR mixture containing 12.5 μl of GoTaq Colorless
Master Mix (catalog number M7142, Promega, WI, USA)
(Reaction Buffer pH 8.5, 400 μM of each dNTP, and
3 mM MgCl2), 1 μl of Taq polymerase, 2 μl of forward
primer (5′-TTTTGAGTTAGGTGTGGGATATA-3′), 2 μl
of reverse biotinylated primer (5′-AAAATCAAAAAA
TTCCCTTTC-3′), and 100 ng of bisulfite-treated gen-
omic DNA. PCR cycling conditions were 95°C for 15 mi-
nutes; 45 cycles of 94°C for 30 seconds, 55°C for
45 seconds, and 72°C for 45 seconds; and finally, 10 mi-
nutes at 72°C and 4°C forever. The biotinylated PCR prod-
uct was purified and made single-stranded to act as a
template in a pyrosequencing reaction as recommended
by the manufacturer using Pyrosequencing Vacuum Tool
(Qiagen, Hilden, Germany). In brief, the PCR product was
bound to a Streptavidin Sepharose HP column, and the
sepharose beads containing the immobilized PCR product
were purified, washed, denatured using 0.2 M NaOH
solution, and washed again. Then, 10 μM of pyrose-
quencing primer (5′AGTTAGGTGTGGGATATAGT-3′)
was annealed to the purified single-stranded PCR product,
and pyrosequencing was performed using a PSQ 96MA
Pyrosequencing System (Qiagen). CpGenome Methylated
DNA (catalog number S7821; Millipore, Darmstadt,
Germany) was used as a positive control. Methylation
level of LINE-1 elements was calculated as the mean per-
centage of the four CpG sites analyzed, as previously de-
scribed [19].Statistical analysis
Distribution of LINE-1 methylation levels was assessed
with the Shapiro–Wilks test, which showed that the data
were not normally distributed (P = 0.017). Accordingly,
the Wilcoxon signed-rank test was used for comparing
average methylation levels of paired ACF and normal mu-
cosa. When comparing global methylation between two
independent groups and between more than two groups,
the Mann–Whitney U-test and Kruskal–Wallis test, re-
spectively, were used. LINE-1 methylation levels are
expressed as median and interquartile range (IQR). All
statistical analyses were performed using SPSS software
(v20; IBM Inc., Armonk, NY, USA) and results were con-
sidered significant at P <0.05.
Results
Baseline characteristics of patients and rectal ACF related
to CRC risk group are detailed in Table 1. As shown, the
adenoma group mainly comprised patients with advanced
adenomas (mean size 12.3 ± 9.8 mm) located throughout
the colorectum. Although 16 patients (40%) with adenoma
had synchronous serrated polyps, the vast majority of them
were small hyperplastic polyps located in the rectosigmoid
colon, which are known to lack clinical significance.
Rectal ACF do not display LINE-1 hypomethylation
To test the role of rectal ACF as a potential precursor le-
sion, we analyzed the LINE-1 methylation levels in rectal
ACF and paired normal rectal and descending colon mu-
cosa from all patients. The median LINE-1 methylation
level of up to three ACF for each patient was considered
for statistical purposes using the Wilcoxon signed-rank
test. As shown in Figure 2A, our data indicated that over-
all, levels of LINE-1 methylation were higher in ACF than
in normal rectal mucosa (80.02% (77.54 to 82.22) versus
76.13% (73.74 to 78.06); P < 0.0001). In fact, only 20 sub-
jects exhibited lower LINE-1 methylation in their rectal
ACF compared with their normal mucosa, and LINE-1 in
rectal ACF was not hypomethylated in any of the three risk
groups (Figure 2B). Likewise, similar results were observed
for LINE-1 methylation levels when comparing rectal ACF
and normal mucosa from descending colon [80.02% (77.54
to 82.22) versus 78.42% (76.51 to 80.33]; P = 0.0002) (see
Additional file 1: Figure S1). We also performed these ana-
lyses stratifying by sex, with similar results for both males
and females (see Additional file 2: Table S1). Interestingly,
there were significant differences in LINE-1 methylation
between dysplastic ACF and hyperplastic ACF [81.46%
(78.75 to 82.97) versus 79.54% (76.88 to 81.79); P = 0.031].
LINE-1 methylation levels in normal colorectal mucosa are
similar in all CC risk groups
To assess the LINE-1 field defect, we compared the
methylation status of LINE-1 in the normal rectal and
Table 1 Baseline characteristics of individuals and aberrant crypt foci in each colon cancer risk group
Control (n = 70) Adenoma (n = 42) Colon cancer (n = 35)
Sex, n (%)
– Female 48 (68.6%) 17 (40.5%) 13 (37.1%)
– Male 22 (31.4%) 25 (59.5%) 22 (62.9%)
Age, years, mean ± SD 58.1 ± 15.3 68.6 ± 9.9 66.8 ± 8.6
Colon cancer location, n (%)
– Sigmoid – – 21 (60%)
– Descending – – 2 (5.7%)
– Transverse – – 1 (2.9%)
– Ascending – – 9 (25.7%)
– Cecum – – 2 (5.7%)
Colon cancer TNM stage, n (%)
– I – – 10 (28.6%)
– II – – 11 (31.4%)
– III – – 13 (37.1%)
– IV – – 1 (2.9%)
Adenoma features (per patient)a
– Tubular, n (%) – 28 (70%) 11 (31.4%)
– Tubulovillous, n (%) – 7 (17.5%) 1 (2.9%)
– Villous, n (%) – 5 (12.5%) 0 (0%)
– High-grade dysplasia, n (%) – 11 (27.5%) 5 (14.3%)
– Adenoma size, mean (mm) ± SD – 12.3 ± 9.8 8.4 ± 5
– Number of adenomas per patient, mean ± SD (range) – 2.4 ± 2 (1 to 9) 1.2 ± 1.2 (1 to 4)
Advanced adenomab, n (%) 22 (55%) 7 (20%)
Adenoma location (per patient)c, n (%)
– Rectum – 12 (30%) 2 (5.7%)
– Sigmoid – 10 (25%) 3 (8.6%)
– Descending – 5 (12.5%) 3 (8.6%)
– Transverse – 5 (12.5%) 2 (5.7%)
– Ascending – 5 (12.5%) 2 (5.7%)
– Cecum – 3 (7.5%) 0 (0%)
Serrated polyps features (per patient)d
– Recto-sigmoid hyperplastic polyps, n (%) – 12 (30%) 3 (8.6%)
– Proximal serrated polyps, n (%)e – 4 (10%) 5 (14.3%)
– Serrated polyps ≥10 mm, n (%) – 2 (5%) 2 (5.7%)
– Serrated polyps per patient, n, mean ± SD (range) – 1.6 ± 0.8 (1 to 3) 3.1 ± 3.4 (1 to 5)
– Hyperplastic polyp, n (%) – 15 (37.5%) 8 (22.9%)
– Sessile serrated adenoma, n (%) – 1 (%) 0 (0%)
–Traditional serrated adenoma, n (%) – 0 (%) 0 (0%)
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Table 1 Baseline characteristics of individuals and aberrant crypt foci in each colon cancer risk group (Continued)
ACF for molecular study, n 117 76 77
Dysplastic ACF, n (%) 24 (17.4%) 23 (24%) 17 (25%)
Hyperplastic ACF, n (%) 114 (82.6%) 73 (76%) 51 (75%)
ACF, aberrant crypt foci; SD, standard deviation.
aThis referred to 40 individuals in the adenoma group for whom full pathological information about the adenomas was available.
bAdvanced adenoma: ≥10 mm in size, or presence of high-grade dysplasia or villous features.
cIn cases with >1 adenoma, this referred to the location of the most advanced adenoma.
dIncluded hyperplastic polyps, sessile serrated adenomas, and traditional serrated adenomas.
eProximal to the sigmoid colon.
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risk groups (CC, adenoma and healthy controls). Because
the healthy control group was significantly younger than
the adenoma and CC groups (Table 1), we first excluded
an age effect in the level of LINE-1 methylation in normal
mucosa (see Additional file 3: Figure S2). As shown in
Figure 3A, methylation of LINE-1 in normal rectal mucosaFigure 2 Long interspersed element-1 (LINE-1) methylation
status in aberrant crypt foci (ACF) and normal rectal mucosa.
(A) LINE-1 methylation levels in ACF compared with normal rectal
mucosa (NRM) samples. (B) ACF LINE-1 methylation levels compared
with NRM samples stratified by risk group. Box-and-whisker plot
indicating the median methylation level expressed as a percentage
(horizontal line), 25th and 75th percentiles (box), and maximum and
minimum levels (whiskers).was independent of the patient group [healthy controls:
76.73% (73.23 to 78.22); adenoma: 75.34% (73.7 to 77.2);
CC: 77.06% (75.04 to 79.23); P = 0.107] (Table 2). Compar-
able results were obtained when normal mucosa from the
descending colon was considered [healthy controls:
77.67% (75.84 to 80.18); adenoma: 78.45% (77.37 to 79.92);
CC: 80.30% (77.19 to 81.39); P = 0.147] (Table 2). These
analyses were also performed with stratification by sex,
with similar results (see Additional file 2: Table S1).
We also analyzed the potential field defect for LINE-1
methylation by stratifying the results by the distance of
the lesion to the normal mucosa biopsies. As shown in
Table 3, LINE-1 methylation levels in normal mucosaFigure 3 Evaluation of long interspersed element-1 (LINE-1)
methylation in normal colorectal mucosa as a potential field
defect. (A) LINE-1 methylation levels in normal rectal mucosa (NRM)
stratified by colon cancer (CC) risk group. (B) LINE-1 methylation levels
in NRM compared with normal mucosa from the descending colon
(NDM). Box-and-whisker plot indicating the median methylation level
expressed as a percentage (horizontal line), 25th and 75th percentile
(box), and maximum and minimum levels (whiskers).
Table 2 LINE-1 methylation levels in normal mucosa and aberrant crypt foci for each of the three groups of subjects
Healthy controls (n = 70) Adenoma (n = 42) Colon cancer (n = 35) P valuea
Normal rectal mucosa, n/N 62/70 31/42 24/35 0.107
Median (IQR) 76.73% (73.23 to 78.22) 75.34% (73.7 to 77.2) 77.06% (75.04 to 79.23)
Normal descending colon mucosa, n/N 42/70 38/42 21/35 0.147
Median (IQR) 77.67% (75.84 to 80.18) 78.45% (77.37 to 79.92) 80.30% (77.19 to 81.39)
Aberrant crypt foci, n/N 68/70 38/42 24/35 0.409
Median (IQR) 79.41% (77.24 to 81.58) 80.32% (77.45 to 82.82) 81.37% (77.48 to 83.14)
Dysplastic aberrant crypt foci, n/N 15 11 9 0.32
Median (IQR) 80.58% (78.54 to 82.37) 80.99% (79.15 to 83.07) 82.74% (79.83 to 83.43)
Hyperplastic aberrant crypt foci, n/N 53 27 24 0.812
Median (IQR) 79.32% (76.94 to 81.54) 79.59% (76.80 to 82.22) 80.02% (76.50 to 82.55)
IQR, interquartile range; n, number of samples analyzed in each group; N, total number of samples included in each group.
aKruskal–Wallis test was used to assess the level of LINE-1 methylation between the three risk groups.
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or CC.
LINE-1 methylation levels in normal mucosa differ
between colonic segments
Interestingly, when we compared the LINE-1 methyla-
tion status in normal mucosa from different segments of
the colorectum, we found a higher degree of hypome-
thylation in the rectum compared with the descending
colon [76.13% (73.75 to 78.06) versus 78.42% (76.51 to
80.33); P < 0.0001], suggesting different genome-wide
methylation profiles between normal colon and rectal
mucosa (Figure 3B). Stratification by sex did not vary
the results (see Additional file 2: Table S1).
Discussion
Overall, our results argue against the hypothesis that glo-
bal hypomethylation occurs at the earliest stages of co-
lorectal carcinogenesis. Overexpression of β-catenin and
KRAS mutations may indicate that ACF constitute a pre-
malignant stage [16]. Moreover, LINE-1 hypomethylation
is already present at the adenoma stage [15]. Our data
suggest, for the first time, to our knowledge, that the for-
mation of ACF is not triggered by hypomethylation in
LINE-1 elements, and that genome-wide hypomethylation
occurs after ACF formation, most likely during the tran-
sition from non-adenomatous to adenomatous epithelia.
In fact, hypermethylation of LINE-1 elements in ACFTable 3 LINE-1 methylation levels in normal mucosa stratifyin
LINE-1 methylation Patients with proximal
adenoma (n = 10)a
Patients with distal
adenoma (n = 30)a
Normal rectal mucosa 73.87% (72.47 to 75.90) 76.06% (74.78 to 77.33)
Normal descending
mucosa
80.72% (76.62 to 82.68) 78.38% (76.55 to 80.01)
LINE-1 methylation levels are expressed as median (interquartile range, IQR).
aReferred to the splenic flexure.suggests that reversal epigenetic changes occur in these
lesions regardless of their pathogenic progression.
Despite the fact that two previous reports have sug-
gested the existence of LINE-1 hypomethylation field de-
fects in CRC, our results indicate the absence of this
phenomenon in our sample set. Kamiyama and collabora-
tors recently showed that normal colonic mucosa from
patients with synchronous CRC displayed higher hypome-
thylation of LINE-1 compared with patients with solitary
CRC and controls [17]. However, and in line with our re-
sults, there were no differences between the two latter
groups. Another study has shown that normal colorectal
mucosa samples from different risk groups displayed dif-
ferences in LINE-1 methylation that mirrored differences
between their respective tumor specimens [17]. A more
recent study has shown that adjacent mucosa from indi-
viduals with multiple/large serrated polyps display signifi-
cantly lower LINE-1 methylation levels compared with
individuals without such polyps [18]. We tested the hy-
pothesis that LINE-1 methylation in normal mucosa could
be used as a biomarker for risk of sporadic CRC, focusing
on patients with conventional adenomas. By analyzing a
prospective cohort of patients with CC and controls, we
found that our data suggest that methylation status of
LINE-1 in normal mucosa is not a suitable biomarker to
predict CC risk in patients with sporadic cancer. However,
the potential field defect for LINE-1 methylation in pa-
tients with serrated polyps needs further assessment.g by location of the neoplastic lesion
P value Patients with proximala
colon cancer (n = 11)
Patients with distal
colon cancer (n = 24)a
P value
0.087 77.59% (72.78 to 80.12) 77.40% (75.70 to 79.79) 0.794
0.176 77.14% (75.59 to 80.06) 78.59% (76.90 to 79.41) 0.458
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normal mucosa between the descending colon and the
rectum, suggesting different methylation profiling depen-
ding on the colonic segment.
Conclusion
Our results shed some light on the role of genome-wide
methylation in rectal ACF and argue against its utility as
a biomarkers for assessing CC risk.
Additional files
Additional file 1: Figure S1. LINE-1 methylation status in aberrant crypt
foci and normal mucosa from the descending colon. (A) LINE-1 methylation
levels in aberrant crypt foci (ACF) compared to normal mucosa from the
descending colon (NDM). (B) ACF LINE-1 methylation levels compared to
descending mucosa samples according to risk group. Box-and-whisker
plot indicating the median methylation level expressed as a percentage
(horizontal line), 25th and 75th percentile (box), and maximum and minimum
levels (whiskers).
Additional file 2: Table S1. LINE-1 methylation analysis stratified by sex.
Additional file 3: Figure S2. Evaluation of the age-effect for LINE-1
methylation data. Representation of the correlation between LINE-1
methylation levels in normal rectal mucosa and the age of patients.
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